These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 28343792)

  • 1. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus.
    Pratley RE; Rosenstock J; Heller SR; Sinclair A; Heine RJ; Kiljański J; Brusko CS; Duan R; Festa A
    J Diabetes Sci Technol; 2018 Nov; 12(6):1184-1191. PubMed ID: 29893144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
    Karl DM; Gill J; Zhou R; Riddle MC
    Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
    Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
    Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
    Riddle MC; Bolli GB; Home PD; Bergenstal RM; Ziemen M; Muehlen-Bartmer I; Wardecki M; Vinet L; Jeandidier N; Yki-Järvinen H
    Diabetes Technol Ther; 2016 Apr; 18(4):252-7. PubMed ID: 26840338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
    Leiter LA; Gross JL; Chow F; Miller D; Johnson S; Ahrén B;
    J Diabetes Complications; 2017 Aug; 31(8):1283-1285. PubMed ID: 28587789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study).
    Yamada Y; Senda M; Naito Y; Tamura M; Watanabe D; Shuto Y; Urita Y
    Diabetes Obes Metab; 2017 Sep; 19(9):1252-1259. PubMed ID: 28345162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.
    Blevins TC; Barve A; Sun B; Ankersen M
    Diabetes Obes Metab; 2018 Aug; 20(8):1944-1950. PubMed ID: 29656504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship among A1C, hypoglycemia, and hyperglycemia in Japanese with type 2 diabetes--results from continuous glucose monitoring data.
    Morimoto A; Nishimura R; Tsujino D; Taki K; Tajima N; Utsunomiya K
    Diabetes Technol Ther; 2011 Jun; 13(6):667-70. PubMed ID: 21457068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
    Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
    Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.